Stage IV Rectal Cancer


Many Early Onset Colon Cancers are Caused by Genetic Mutations Passed Through Families (January 12, 2017)

One in every six colorectal cancer patients (16 percent) diagnosed under age 50 has at least one inherited genetic mutation that increases his or her cancer risk and many of these mutations could go undetected... Continue Reading

NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer (December 21, 2016)

SIR-Spheres® Y-90 microspheres have just been added as a new treatment option in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for colon cancer... Continue Reading

New Treatment Identified for Locally Advanced Rectal Cancer Has Fewer Side Effects Than Current Standard (January 27, 2016)

The results from a comparative phase III clinical study reported by Polish investigators at the 2016 Gastrointestinal Cancers Symposium in San Francisco have identified an additional treatment option for... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (September 30, 2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (August 24, 2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix... Continue Reading

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment (June 23, 2015)

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs... Continue Reading

New Drug Combination Extends Survival of Patients with Metastatic Colorectal Cancer (June 18, 2015)

A drug developed 50 years ago and abandoned because it was considered to be too toxic has gained a second life in an international clinical trial. Research led by scientists at Dana-Farber Cancer Institute... Continue Reading

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer (March 17, 2015)

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical... Continue Reading

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer (February 19, 2015)

CancerConnect News: The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium,... Continue Reading

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer (January 16, 2015)

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal... Continue Reading

Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer (January 15, 2015)

According to the results of a clinical trial presented at the 2015 Gastrointestinal Cancers Symposium in San Francisco, treatment of patients with metastatic colorectal cancer with a four-drug chemotherapy... Continue Reading

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer (November 3, 2014)

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival... Continue Reading

Novel Agent Granted Fast Track Designation for Refractory Metastatic Colorectal Cancer (October 23, 2014)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. According... Continue Reading

New Online Support Group for People Affected by Gastrointestinal Conditions: IBS, Crohn’s, UC, GERD, Cancer and More (August 14, 2014)

Are you suffering from a gastrointestinal (GI) tract condition? You are not alone! TheGIConnection is now available for patients, caregivers, and health consumers as an up to date online information resource... Continue Reading

Chemotherapy Regimens Paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux®... Continue Reading

Web Chat on “Using Radiation to Treat Colorectal Cancers Metastasized to the Liver,” with Sarah Cannon Expert Andrew Kennedy, MD (April 2, 2014)

  Sarah Cannon Radiation Oncology Physician-in-Chief Andrew Kennedy, MD, discusses metastatic colorectal cancer and answers participants’ questions during a live Web chat recorded on April 2, 2014.... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS